- Home
- RFL vs VNRX Comparison
RFL vs VNRX Comparison
Compare RFL & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFL | VNRX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 31.9M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RFL | VNRX |
|---|---|---|
| Price | $1.34 | $0.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 92.9K | ★ 1.5M |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.28 | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | $917,000.00 | ★ $1,233,511.00 |
| Revenue This Year | N/A | $68.22 |
| Revenue Next Year | N/A | $382.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 43.96 | ★ 59.10 |
| 52 Week Low | $1.12 | $0.17 |
| 52 Week High | $3.19 | $0.94 |
Technical Indicators
Market Signals| Indicator | RFL | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 36.92 |
| Support Level | $1.15 | $0.17 |
| Resistance Level | $1.38 | $0.27 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 30.00 | 17.93 |
Price Performance
Historical ComparisonAbout RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.